Streetbeat News

Analyst Ratings

JELD

Barclays analyst Matthew Bouley maintains an Equal-Weight rating on JELD-WEN Holding (NYSE:JELD) and lowers the price target from $18 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:26 pm

IFF

Barclays analyst Lauren Lieberman maintains an Underweight rating on Intl Flavors & Fragrances (IFF) and lowers the price target from $60 to $57.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:25 pm

IAS

Barclays analyst Raimo Lenschow maintains an Equal-Weight rating on Integral Ad Science (NASDAQ:IAS) and lowers the price target from $21 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:22 pm

GOLD

A significant amount of unusual options activity has been observed for Barrick Gold (NYSE:GOLD), with a bearish stance being taken by a majority of investors. Of the 15 strange trades detected, 53% were bearish and 46% bullish. The total amount for the 3 puts was $124,308 and for the 12 calls was $648,000. Whales have been targeting a price range from $13.0 to $17.0 for Barrick Gold over the last 3 months. The price of GOLD is currently down -0.69% at $15.12. UBS, BMO Capital, and Jefferies have maintained their Buy, Outperform, and Hold ratings respectively.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:22 pm

CAT

A whale investor has taken a bearish stance on Caterpillar (NYSE:CAT), with 72% of the spotted trades being bearish. The trades include 6 puts amounting to $447,980 and 5 calls amounting to $338,960. The targeted price range for Caterpillar over the last 3 months is from $262.5 to $320.0. The current price of CAT is down -1.08% at $269.88, and RSI indicators suggest it may be approaching oversold. The next earnings are expected in 14 days.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:22 pm

MRNA

A significant bearish stance has been taken on Moderna (NASDAQ:MRNA) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is split, with 40% bullish and 60% bearish. The whales have been targeting a price range from $79.0 to $150.0 for Moderna over the last 3 months. Argus Research maintains their Buy rating on Moderna, with a price target of $140.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:22 pm

HLMN

Barclays analyst Matthew Bouley maintains an Overweight rating on Hillman Solns (NASDAQ:HLMN) but has lowered the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:22 pm

GMED

Barclays analyst Matt Miksic maintains an Overweight rating on Globus Medical (NYSE:GMED) and raises the price target from $77 to $86.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:20 pm

FBIN

Barclays analyst Matthew Bouley maintains an Overweight rating on Fortune Brands (NYSE:FBIN) but has lowered the price target from $89 to $74.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:19 pm

JKHY

Goldman Sachs has downgraded Jack Henry & Associates from Neutral to Sell and set a price target of $140. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:17 pm